Analysts’ Recent Ratings Changes for Ralliant (RAL)

Several analysts have recently updated their ratings and price targets for Ralliant (NYSE: RAL):

• 5/31/2026 – Ralliant was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/27/2026 – Ralliant was downgraded by Vertical Research from “buy” to “hold”. They now have a $65.00 price target on the stock.
• 5/23/2026 – Ralliant was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/20/2026 – Ralliant had its price target raised by TD Cowen from $55.00 to $70.00. They now have a “buy” rating on the stock.
• 5/14/2026 – Ralliant had its price target raised by Morgan Stanley from $45.00 to $68.00. They now have an “overweight” rating on the stock.
• 5/13/2026 – Ralliant had its price target raised by Royal Bank Of Canada from $47.00 to $64.00. They now have a “sector perform” rating on the stock.
• 5/13/2026 – Ralliant had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $65.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Ralliant had its price target raised by Citigroup Inc. from $51.00 to $70.00. They now have a “buy” rating on the stock.
• 5/13/2026 – Ralliant had its price target raised by Barclays PLC from $52.00 to $67.00. They now have an “overweight” rating on the stock.
• 5/13/2026 – Ralliant had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $68.00 price target on the stock, up from $53.00.
• 5/4/2026 – Ralliant had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 4/13/2026 – Ralliant was upgraded by Zacks Research from “strong sell” to “hold”.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio is presently -1.83%.

Insider Activity at Ralliant

In other news, SVP Karen M. Bick sold 2,530 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $46.50, for a total value of $117,645.00. Following the completion of the sale, the senior vice president directly owned 42,652 shares of the company’s stock, valued at approximately $1,983,318. This represents a 5.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.42% of the company’s stock.

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.